Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MAGNEVIST is an injectable small-molecule contrast agent approved by the FDA in 1988. The drug is used as a diagnostic aid in medical imaging, though specific indications are not documented in the available data. It is administered via injection to enhance visualization in diagnostic imaging procedures.
Product is approaching loss of exclusivity with moderate competitive pressure (30), suggesting team focus is shifting toward lifecycle management and defense strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Gadobutrol Magnevist-controlled Body Study
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Magnevist Post-marketing Surveillance in Japan
Multihance Versus Magnevist in Breast MRI
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Worked on MAGNEVIST at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
MAGNEVIST currently shows zero linked job openings, reflecting its mature, late-stage lifecycle. Roles available are typically in defensive commercial strategy, market access, and regulatory compliance rather than growth-oriented positions.